Tagami, Nami
Uchiyama, Michihiro
Suzuki, Kenshi
Shirai, Heigoroh
Seto, Takeshi
Nishina, Satoshi
Iida, Shinsuke http://orcid.org/0000-0002-4951-960X
Funding for this research was provided by:
Sanofi K.K.
Article History
Received: 31 October 2023
Revised: 13 May 2024
Accepted: 21 May 2024
First Online: 29 May 2024
Declarations
:
: Shinsuke Iida has received lecture fees from Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb K.K., and Pfizer Japan Inc.; trust research/joint research funds from Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb K.K., Pfizer Japan Inc., Daiichi Sankyo Co. Ltd., Amgen K.K., AbbVie GK, Caelum, Shionogi & Co. Ltd., GlaxoSmithKline K.K., and Celgene; and scholarship funds from Chugai Pharmaceutical Co. Ltd. Kenshi Suzuki has received lecture fees from Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Amgen K.K., Novartis Pharma K.K., Sanofi K.K., Bristol-Myers Squibb K.K., AbbVie GK, and Janssen Pharmaceutical K.K.; consultancy fees from Amgen K.K., Takeda Pharmaceutical Co. Ltd., and Bristol-Myers Squibb K.K.; and trust research/joint research funds from Bristol-Myers Squibb K.K. Nami Tagami, Heigoroh Shirai, Takeshi Seto and Satoshi Nishina are employees of Sanofi K.K. Satoshi Nishina holds stock in Sanofi. Michihiro Uchiyama has no conflicts of interest to declare.